|
Irinotecan in Treating Aging Patients With Solid Tumors Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Irinotecan in Treating Aging Patients With Solid Tumors conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Irinotecan in Treating Aging Patients With Solid Tumors Clinical research trials and Irinotecan in Treating Aging Patients With Solid Tumors medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Irinotecan in Treating Aging Patients With Solid Tumors. Irinotecan in Treating Aging Patients With Solid Tumors Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Irinotecan in Treating Aging Patients With Solid Tumors clinical trial. Subjects often receive the most expert healthcare possible for their Irinotecan in Treating Aging Patients With Solid Tumors condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Irinotecan in Treating Aging Patients With Solid Tumors  Irinotecan in Treating Aging Patients With Solid Tumors
Irinotecan in Treating Aging Patients With Solid Tumors
For Condition: unspecified adult solid tumor, protocol specific
Status: No longer recruiting
Sponsor(s): Cancer and Leukemia Group B , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Aging may affect the way these drugs work. PURPOSE: Phase I trial to determine the relationship between aging and the effectiveness of irinotecan in treating patients who have solid tumors.
Details: OBJECTIVES: - Determine whether there is a relationship between the pharmacokinetic characteristics of irinotecan and aging in patients with non-hematologic malignancies. - Determine whether there is a relationship between the toxic effects of this drug and aging in these patients. - Determine whether the relationship between genotype (UGT1A1, CYP3A, and other relevant genes) and phenotype (pharmacokinetics, toxicity) is affected by aging in these patients treated with this drug. - Analyze data collected on the co-morbid conditions and concurrent medications in these patients treated with this drug. OUTLINE: This is a multicenter study. Patients are stratified according to age (18 to 55 vs 70 and over). Patients receive irinotecan IV over 90 minutes once weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for survival. PROJECTED ACCRUAL: A total of 140 patients (70 per stratum) will be accrued for this study within 3.5 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed non-hematologic malignancy - Brain metastases or primary brain tumors are eligible provided patient is not receiving steroids or antiepileptic medications PATIENT CHARACTERISTICS: Age: - 18 to 55 or 70 and over Performance status: - CTC 0-2 Life expectancy: - Not specified Hematopoietic: - Granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than upper limit of normal (ULN) - SGOT no greater than ULN Renal: - Creatinine no greater than ULN Other: - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 4 weeks since prior chemotherapy (6 weeks for nitrosourea) - No more than 1 prior chemotherapy regimen for metastatic disease (no limit if administered in the adjuvant setting) - No prior camptothecin Endocrine therapy: - See Disease Characteristics Radiotherapy: - At least 4 weeks since prior radiotherapy - No concurrent radiotherapy, including for palliation Surgery: - At least 4 weeks since prior major surgery
Total Enrollment:
Location and Contact Information:
Overall Study Official:
StuartLichtman, Study Chair, North Shore University Hospital
Mount Sinai Medical Center, NY
New York City, New York, 10029
United States
Veterans Affairs Medical Center - Columbia (Truman Memorial)
Columbia, Missouri, 65201
United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198-7680
United States
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
United States
Veterans Affairs Medical Center - Buffalo
Buffalo, New York, 14215
United States
CCOP - Southeast Cancer Control Consortium
Winston Salem, North Carolina, 27104-4241
United States
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
United States
CCOP - Christiana Care Health Services
Wilmington, Delaware, 19899
United States
Missouri Baptist Cancer Center
St. Louis, Missouri, 63131
United States
North Shore University Hospital
Manhasset, New York, 11030
United States
Marlene and Stewart Greenebaum Cancer Center, University of Maryland
Baltimore, Maryland, 21201
United States
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210-1240
United States
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
United States
Veterans Affairs Medical Center - White River Junction
White River Junction, Vermont, 05009
United States
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
Weill Medical College of Cornell University
New York City, New York, 10021
United States
MBCCOP - University of Illinois at Chicago
Chicago, Illinois, 60612-7323
United States
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, 46601
United States
Veterans Affairs Medical Center - Minneapolis
Minneapolis, Minnesota, 55417
United States
University of Minnesota Cancer Center
Minneapolis, Minnesota, 55455
United States
Green Mountain Oncology Group
Bennington, Vermont, 05201
United States
University of Massachusetts Memorial Medical Center - University Campus
Worcester, Massachusetts, 01655
United States
Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756-0002
United States
CCOP - North Shore University Hospital
Manhasset, New York, 11030
United States
Veterans Affairs Medical Center - San Francisco
San Francisco, California, 94121
United States
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224
United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
United States
Lifespan: The Miriam Hospital
Providence, Rhode Island, 02906
United States
Vermont Cancer Center
Burlington, Vermont, 05401-3498
United States
Comprehensive Cancer Center at Wake Forest University
Winston Salem, North Carolina, 27157-1082
United States
UCSF Comprehensive Cancer Center
San Francisco, California, 94143-0128
United States
Cedars-Sinai Medical Center
Los Angeles, California, 90048
United States
State University of New York - Upstate Medical University
Syracuse, New York, 13210
United States
Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242-1009
United States
Lombardi Cancer Center
Washington D.C., District of Columbia, 20007
United States
Barnes-Jewish Hospital
St. Louis, Missouri, 63110
United States
CCOP - Mount Sinai Medical Center
Miami, Florida, 33140
United States
Veterans Affairs Medical Center - Durham
Durham, North Carolina, 27705
United States
MBCCOP - Massey Cancer Center
Richmond, Virginia, 23298-0037
United States
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Rebecca and John Moores UCSD Cancer Center
La Jolla, California, 92093-0658
United States
Walter Reed Army Medical Center
Washington D.C., District of Columbia, 20307-5000
United States
Veterans Affairs Medical Center - Chicago (Westside Hospital)
Chicago, Illinois, 60612
United States
Veterans Affairs Medical Center - Syracuse
Syracuse, New York, 13210
United States
Ellis Fischel Cancer Center - Columbia
Columbia, Missouri, 65203
United States
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
Syracuse, New York, 13217
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
United States
Additional Information:
Study ID Numbers: CDR0000068995; CLB-60001
Study Start Date:
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00026195
Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Stress Management Training in Patients Undergoing Radiation Therapy for Cancer
2. E7070 in Treating Patients With Solid Tumors
3. Radiofrequency Ablation in Treating Patients With Bone Metastases
4. Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C
5. R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors
Related Studies:
Other unspecified adult solid tumor, protocol specific Clinical Trials
Other Nevada Clinical Trials
Other Las Vegas Clinical Trials
Irinotecan in Treating Aging Patients With Solid Tumors
|
|
|
|
|
|
|
|
